UTHR

Q: What is the price of United Therapeutics (UTHR) today?

The price of United Therapeutics (UTHR) today is $ 485.77, with return of 31.77% compared to the last year. The price of United Therapeutics (UTHR) started the year trading around $ 352.84 and today it is at $ 485.77. Follow the real-time price chart, the historical price of United Therapeutics (UTHR) and international markets.

Q: When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not distribute dividends in the last year.

Q: Is United Therapeutics (UTHR) worth it?

Currently, United Therapeutics (UTHR) is priced at $ 485.77, with a P/E of 16.43%, representando um desvio de 1,611% em relação ao seu P/L médio histórico. No último ano, a ação apresentou a variation of 31.77 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 31.77%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy United Therapeutics (UTHR) stock?

Investing in stocks of United Therapeutics (UTHR) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of United Therapeutics (UTHR) yield today?

The yield of United Therapeutics (UTHR) was 16.05% in the last month, 31.77% in the last year and 258.39% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of United Therapeutics (UTHR) today, the total investment would be $ 48,576.70, based on the current price of $ 485.77.If past performance were to repeat, the return on your investment would be:In 1 year: $ 64,009.52In 5 years: $ 174,094.04In 10 years: $ 154,600.21It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

United Therapeutics Corporation

Price

$ 485.77

return (12m)

31.77%

p/e

16.43

p/bv

3.17

DIVIDEND YIELD

0.00%

price UTHR

UTHR

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of UTHR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

16.05%

3 months

59.09%

1 year

31.77%

2 years

110.20%

5 years

258.39%

10 years

218.26%

Fundamentals UTHR

review the fundamentals of United Therapeutics shares

P/E

16.43

Sector: -3.40 Industry: -3.40

P/SALES RATIO (PSR)

6.68

Sector: -3.36 Industry: -3.36

P/BV

3.17

Sector: 1.98 Industry: 1.98

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

17.30%

Sector: -62.78% Industry: -62.78%

ROE

19.30%

Sector: -68.26% Industry: -68.26%

ROIC

28.19%

Sector: -1,140.39% Industry: -1,140.39%

NET MARGIN

40.65%

Sector: -41.80% Industry: -41.80%

GROSS MARGIN

88.59%

Sector: 39.33% Industry: 39.33%

OPERATING MARGIN

48.65%

Sector: -41.58% Industry: -41.58%

P/EBITDA

11.78

Sector: -3.48 Industry: -3.48

P/EBIT

12.36

Sector: -3.60 Industry: -3.60

P/ASSET

2.84

Sector: 1.42 Industry: 1.42

BVPS

149.78

Sector: 1.79 Industry: 1.79

EPS

28.90

Sector: -2.05 Industry: -2.05

EQUITY RATIO

0.90

Sector: 0.42 Industry: 0.42

CAGR REVENUE 5 YEARS

16.10%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

19.83%

Sector: - Industry: -

FAIR VALUE OF United Therapeutics ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 485.77

Fair Value

$ 0.00

Upside Return potential.

-35.76%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals UTHR

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	19.42	0.00	0.00%	2.51%	$ 487.73 B	27.26%
PFE	14.23	1.50	10.56%	6.95%	$ 139.89 B	15.65%
ABBV	102.44	-2,793.44	-2,726.81%	2.97%	$ 385.49 B	6.45%
NVO	13.73	7.92	57.70%	3.54%	$ 211.67 B	32.78%
MRK	12.83	0.00	0.00%	3.31%	$ 244.20 B	29.63%
AZN	30.03	6.14	20.45%	1.72%	$ 282.28 B	16.17%
BMY	15.59	5.06	32.47%	5.36%	$ 94.17 B	12.57%
GILD	19.41	7.34	37.80%	2.48%	$ 157.41 B	27.88%
ZTS	20.40	10.02	49.11%	1.58%	$ 54.07 B	28.21%
HALO	13.82	16.33	118.17%	0.00%	$ 8.23 B	47.91%
REGN	17.17	2.54	14.79%	0.35%	$ 78.61 B	32.13%
AMGN	25.92	18.88	72.82%	2.78%	$ 181.60 B	19.47%
VRTX	29.73	6.31	21.22%	0.00%	$ 109.25 B	31.35%
MCK	26.63	-185.79	-697.75%	0.34%	$ 107.39 B	1.04%
ADMA	19.60	9.52	48.57%	0.00%	$ 4.11 B	42.87%
CAH	31.26	-18.26	-58.40%	0.97%	$ 49.86 B	0.68%
BIIB	16.02	1.42	8.83%	0.00%	$ 25.77 B	15.98%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

UTHR Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT THE COMPANY United Therapeutics

United Therapeutics Corporation

Average user rating I10

4.0 (5 people)

United States

29 years

Founded: 1996

1999

Time since IPO - 26 years

920

Employees

The Company United Therapeutics Corporation (United States), is listed on Nasdaq with a market cap of $ 20.89 Billions, having an equity of $ 6.59 Billions.

With a total of 920 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 3.13 Billions, which generated a profit in the amount of $ 1.27 Billion.

As for its main indicators, the Company has a P/E ratio of 16.43, a P/BV ratio of 3.17 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker UTHR.

Market cap

$ 20.89 Billions

Equity

$ 6.59 Billions

US$ 6,590,200,000.00

Assets

$ 7.35 Billions

US$ 7,351,100,000.00

Total Shares Outstanding

44.00 Millions

44,000,000

Average Daily Trading Volume

$ 676.34 Thousand

US$ 676,341.74

Sector

Health Care

Industry

Biotechnology

UTHR

UTHR revenue and profits

Financial Results UTHR

DRAG THE FRAME TO SEE MORE DATA

UTHR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 889.28 43,05% (12M)

P/E

26.63

0.34%

ROE

-697.75%

P/BV

-185.79

CAH - Cardinal Health

$ 213.73 77,50% (12M)

P/E

31.26

0.97%

ROE

-58.40%

P/BV

-18.26

JNJ - Johnson & Johnson

$ 206.67 39,00% (12M)

P/E

19.42

2.51%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 105.66 8,77% (12M)

P/E

12.83

3.31%

ROE

0.00%

P/BV

0.00

PFE - Pfizer

$ 25.72 8,48% (12M)

P/E

14.23

6.95%

ROE

10.56%

P/BV

1.50

ABBV - AbbVie

$ 231.80 32,43% (12M)

P/E

102.44

2.97%

ROE

-2,726.81%

P/BV

-2,793.44

AZN - AstraZeneca

$ 93.24 43,50% (12M)

P/E

30.03

1.72%

ROE

20.45%

P/BV

6.14

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 889.28 43,05% (12 M)

P/L

26.63

0.34%

ROE

-697.75%

P/VP

-185.79

CAH - Cardinal Health

$ 213.73 77,50% (12 M)

P/L

31.26

0.97%

ROE

-58.40%

P/VP

-18.26

JNJ - Johnson & Johnson

$ 206.67 39,00% (12 M)

P/L

19.42

2.51%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 105.66 8,77% (12 M)

P/L

12.83

3.31%

ROE

0.00%

P/VP

0.00

PFE - Pfizer

$ 25.72 8,48% (12 M)

P/L

14.23

6.95%

ROE

10.56%

P/VP

1.50

ABBV - AbbVie

$ 231.80 32,43% (12 M)

P/L

102.44

2.97%

ROE

-2,726.81%

P/VP

-2,793.44

AZN - AstraZeneca

$ 93.24 43,50% (12 M)

P/L

30.03

1.72%

ROE

20.45%

P/VP

6.14

Frequently Asked Questions

What is the price of United Therapeutics (UTHR) today?

The price of United Therapeutics (UTHR) today is $ 485.77, with return of 31.77% compared to the last year. The price of United Therapeutics (UTHR) started the year trading around $ 352.84 and today it is at $ 485.77. Follow the real-time price chart, the historical price of United Therapeutics (UTHR) and international markets.

When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not distribute dividends in the last year.

Is United Therapeutics (UTHR) worth it?

Currently, United Therapeutics (UTHR) is priced at $ 485.77, with a P/E of 16.43%, representando um desvio de 1,611% em relação ao seu P/L médio histórico. No último ano, a ação apresentou a variation of 31.77 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 31.77%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy United Therapeutics (UTHR) stock?

Investing in stocks of United Therapeutics (UTHR) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of United Therapeutics (UTHR) yield today?

The yield of United Therapeutics (UTHR) was 16.05% in the last month, 31.77% in the last year and 258.39% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of United Therapeutics (UTHR) today, the total investment would be $ 48,576.70, based on the current price of $ 485.77.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 64,009.52
In 5 years: $ 174,094.04
In 10 years: $ 154,600.21

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

UTHR

United Therapeutics Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return of UTHR

review the fundamentals of United Therapeutics shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY RATIO

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT THE COMPANY United Therapeutics

United Therapeutics Corporation

United States

29 years

1999

920

PROFIT X PRICE UTHR

Financial Results UTHR

UTHR cash flow

asset growth - UTHR

UTHR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

Frequently Asked Questions